Mollie Goldman

Mollie Goldman

Auto-generated profile, based on publicly available information

Mollie Goldman

Department of Urology, University Hospitals Cleveland Medical Center, Case Western Reserve University School of Medicine , Cleveland, OH

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2025 in JU Open Plus
Verified
Journal Article
Open access
MGMollie Goldman
Mollie Goldman
CACamilo Arenas-Gallo
Camilo Arenas-Gallo
ABAdithya Balasubramanian
Adithya Balasubramanian
ACAnyull D. Bohorquez Caballero
Anyull D. Bohorquez Caballero
PLPatrick Lewicki
Patrick Lewicki
JSJonathan E. Shoag
Jonathan E. Shoag
Background: MRI has emerged as an important tool for prostate cancer early detection. Despite its utility, insurance coverage for prebiopsy MRI is variable, with previous studies suggesting dramatic underutilization. Methods: MarketScan Commercial and Medicare Claims Database was used to identify men who underwent a prostate MRI within 9 months preceding their prostate biopsy from January 2012 to December 2021. Exclusion criteria included a prior prostate cancer (PCa) diagnosis and previous PCa treatment. We examined national trends in MRI utilization according to insurance and prior biopsy status and used multivariable logistic regression to identify predictors of its use. As a supplemental analysis, we explored the probability of treatment with radiation or radical prostatectomy according to prebiopsy MRI status. Results: We identified 252,962 prostate biopsy claims between 2012 and 2021. Prebiopsy MRI use increased from 1.5% of total biopsies to 30.3% in 2021. Among patients who had a prior biopsy, the proportion rose from 2.7% to 59.0%. On multivariable analysis, having undergone a previous biopsy (odds ratio [OR]: 6.04, 95% confidence interval [95% CI]: 5.24 to 6.96; P < .001) and residing in an urban area (OR: 1.95, 95%CI: 1.67-2.28; P < .001) were both independent predictors of having an MRI before biopsy. No differences in the use of prebiopsy MRI were observed between Medicare and commercial insurance holders (OR: 1.07, 95%CI: 0.99-1.15; P = .112). Among patients who had undergone a prior biopsy, the probability of undergoing a subsequent radical prostatectomy was higher for patients who had an MRI before their biopsy (15.9%, 95%CI: 15.0%-16.8%) as compared with patients who did not have a prebiopsy MRI (10.4%, 95%CI: 9.8%-10.9%). Conclusions: The use of prebiopsy MRI for prostate cancer diagnosis has increased over the past decade, particularly in patients who had undergone a prior negative biopsy. Having undergone an MRI was associated with an increase in the odds of treatment, particularly in those with a prior biopsy, suggesting an increase in the detection of higher-grade cancers associated with MRI use at a population level.

1 September 2025 in JNCI Cancer Spectrum
Verified
Journal Article
Open access
AZAlec Zhu
Alec Zhu
SRStephen Rhodes
Stephen Rhodes
BABashir Al Hussein Al Awamlh
Bashir Al Hussein Al Awamlh
RVRandy A Vince
Randy A Vince
NZNicholas Zaorsky
Nicholas Zaorsky
JSJonathan E Shoag
Jonathan E Shoag
Background: Prior studies evaluating racial disparities in cancer outcomes used regional measures of deprivation when accounting for socioeconomic status, which lack granularity. We evaluated differences in prostate cancer mortality between Black and White men using individual home prices in addition to regional metrics to understand the impact of individual wealth on prostate cancer outcomes. Methods: Individuals diagnosed with prostate cancer between January 2004 and December 2016 in the Ohio Cancer Incidence Surveillance System were included. Individual home addresses were linked to the Area Deprivation Indices and home prices using data from an online real estate marketplace. Using inverse probability weighting to balance patient characteristics, we assessed differences in prostate cancer–specific mortality or other-cause mortality between Black and White men after accounting for clinical characteristics and social determinants of health (insurance, area deprivation, and home price). Results: We identified 70 660 (85%) White and 12 192 (15%) Black men with prostate cancer. Black race was associated with a higher risk of prostate cancer–specific mortality in models that adjusted for age and year at diagnosis (subdistribution hazard ratio = 1.45, 95% CI = 1.45 to 1.57) and with the addition of cancer variables (subdistribution hazard ratio = 1.16, 95% CI = 1.06 to 1.26). In models that incorporate social determinants of health, however, rates of prostate cancer–specific mortality and other-cause mortality were not statistically significantly higher for Black men (subdistribution hazard ratios = 1.10, 95% CI = 0.98 to 1.24, and 1.02, 95% CI = 0.95 to 1.09), respectively. Conclusions: After accounting for clinical characteristics and social determinants of health at the individual level, Black men were not at increased risk of prostate cancer mortality relative to White men.